USPTO Grants Notice of Allowance to Anixa Bioscience’s Ovarian Cancer Vaccine
The potential vaccine is being developed in partnership with the Cleveland Clinic and the NCI.
Stock.adobe.com
The United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for Anixa Bioscience’s patent application for its ovarian cancer vaccine technology.1 Specifically, the application covers the use of targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2). While a Notice of Allowance does not guarantee registration of the patent, it is a step in the right direction.
The potential vaccine is being developed in partnership with the Cleveland Clinic and the National Cancer Institute. According to Anixa, the vaccine is an attempt to illicit an AMHR2-specific immune response and could be highly effective in people with BRCA mutations.
In a press release, Anixa Biosciences chairman and CEO Dr. Amit Kumar said, “Receiving this Notice of Allowance from the USPTO is a significant milestone in our mission to develop a preventative and therapeutic ovarian cancer vaccine. The allowed claims provide broad protection for the various components and delivery mechanisms of our vaccine technology. This strengthens our intellectual property position and supports the continued advancement of our program."
Anixa has other ovarian cancer in development, including a CAR-T therapy in partnership with the Moffitt Cancer Center.2 In February, Anixa announced that it had dosed the final patient in the third cohort of an ongoing Phase I trial for the treatment.
In a press release issued at the time, Kumar said, “With the completion of the third cohort, we are gaining important insights into the potential of CAR-T therapy for ovarian cancer. Increasing the dose is a key step in evaluating the therapy's effectiveness while ensuring patient safety. Additionally, the recent approval of our protocol amendment allows eligible patients to receive a second dose if they may benefit from it. This amendment also expands enrollment criteria to include rare ovarian cancer subtypes, making the therapy accessible to more patients. Now, all eligible participants can receive a second dose without requiring separate IND approvals, helping us better assess the full potential of this treatment. As we move forward with the fourth cohort, we remain committed to advancing our CAR-T program with the goal of improving treatment options for ovarian cancer patients."
Earlier that month, Anixa announced that the approval of an amendment to the study’s protocol which allowed patients in the study to potentially receive a second dose of the therapy.3
In a press release issued at the time, Kumar said, “"We are excited about the approval of this protocol amendment, as it allows us to potentially enhance the efficacy of our CAR-T therapy by providing a second dose to patients who might benefit from it and to treat additional rare types of ovarian cancer. This is a significant step in optimizing the treatment for ovarian cancer, and we look forward to continuing our work with Moffitt Cancer Center as we strive to improve outcomes for patients facing this difficult disease.”
Dr. Robert Wenham, chair of the Department of Gynecologic Oncology at Moffitt and the principal investigator of the trial, added, "This amendment is a crucial development in our ongoing efforts to advance the treatment of ovarian cancer with CAR-T therapy. The ability to administer a second dose to patients who show potential for additional benefit provides us with more flexibility and an opportunity to further evaluate the effectiveness of this innovative therapy."
SOURCE
- Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025. https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-uspto-for-ovarian-cancer-vaccine-302408680.html
- Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial. Anixa Biosciences, Inc. February 26, 2025. Accessed March 24, 2025. https://www.prnewswire.com/news-releases/anixa-biosciences-and-moffitt-cancer-center-complete-dosing-in-third-cohort-in-ovarian-cancer-car-t-clinical-trial-302385536.html
- Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial. Anixa Biosciences, Inc. February 18, 2025. Accessed March 24, 2025. https://www.prnewswire.com/news-releases/anixa-biosciences-announces-approval-of-protocol-amendment-for-ovarian-cancer-car-t-clinical-trial-302377533.html
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
